Gene-Specific Demethylation as Targeted Therapy in MDS
Technical Report,15 Jun 2016,14 Jun 2017
Beth Israel Deaconess Medical Center Boston United States
Pagination or Media Count:
Myelodysplastic Syndromes MDS are a group of clonal hematopoietic disorders characterized by bone marrow failure and risk of progression to Acute Myeloid Leukemia AML in approximately 30 percent of the cases. Aberrant DNA methylation is considered a dominant mechanism for Tumor Suppressor Genes silencing during MDS evolution to AML, but the causes leading to aberrant DNA methylation remain elusive. This proposal builds on our recent discovery of a novel class of RNAs, the DiRs or DNMT1-interacting RNAs, involved in cell type-specific DNA methylation patterns. Based on these findings, we hypothesize that DNA methylation changes can be corrected by RNAs.
- Medicine and Medical Research